[The present status and problems of Helicobacter pylori eradication therapy with a special reference to gastric cancer].
Since the eradication therapy of Helicobacter pylori(H. pylori) for peptic ulcer was covered by Japanese health insurance at 2000 November, this therapy has been generalized in Japan. However, some problems have cropped up at the time, for example, emergence of clarithromycin resistant bacterium etc. On the other hand, investigation of relation between H. pylori and gastric cancer is making progress. Uemura, et al. demonstrated H. pylori had an important role for gastric carcinogenesis by the elegant prospective study in 2001. Under the present circumstances, the Japanese society of Helicobacter Research has to reconsider the guideline for eradication therapy. In this paper, we would like to state the present status and problems of eradication therapy of the current guideline for eradication therapy, especially focusing on gastric cancer.
Shimoyama
Takashi
T
Department of Gastroenterology, Hyogo College of Medicine.
Fukuda
Yoshihiro
Y
Sakagami
Takashi
T
D000818:Animals; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D017410:Practice Guidelines as Topic; D013274:Stomach Neoplasms / Q000209:etiology*